Free Trial

Larimar Therapeutics (LRMR) Stock Forecast & Price Target

Larimar Therapeutics logo
$4.01 +0.03 (+0.75%)
(As of 12/20/2024 05:40 PM ET)

Larimar Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
11

Based on 11 Wall Street analysts who have issued ratings for Larimar Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 10 have given a buy rating, and 1 has given a strong buy rating for LRMR.

Consensus Price Target

$20.43
409.44% Upside
According to the 11 analysts' twelve-month price targets for Larimar Therapeutics, the average price target is $20.43. The highest price target for LRMR is $26.00, while the lowest price target for LRMR is $14.00. The average price target represents a forecasted upside of 409.44% from the current price of $4.01.
Get the Latest News and Ratings for LRMR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Larimar Therapeutics and its competitors.

Sign Up

LRMR Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.43$20.43$20.00$11.83
Forecasted Upside409.44% Upside233.26% Upside182.89% Upside176.48% Upside
Consensus Rating
Buy
Buy
Buy
Buy

LRMR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LRMR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Larimar Therapeutics Stock vs. The Competition

TypeLarimar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.09
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside409.44% Upside25,828.60% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent LRMR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/16/2024HC Wainwright
2 of 5 stars
E. White
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00+266.75%
11/19/2024William Blair
2 of 5 stars
 Reiterated RatingOutperform
10/16/2024Oppenheimer
3 of 5 stars
 Initiated CoverageOutperform$26.00+250.40%
10/3/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00+249.76%
9/4/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/4/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$16.00+131.21%
5/31/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$25.00 ➝ $25.00+214.07%
5/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$10.00 ➝ $14.00+74.13%
4/3/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Park
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/3/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$25.00+239.67%
2/20/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Jubinville
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/17/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$12.00 ➝ $14.00+283.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:24 PM ET.


LRMR Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Larimar Therapeutics is $20.43, with a high forecast of $26.00 and a low forecast of $14.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LRMR shares.

According to analysts, Larimar Therapeutics's stock has a predicted upside of 409.44% based on their 12-month stock forecasts.

Larimar Therapeutics has been rated by research analysts at HC Wainwright, Oppenheimer, Wedbush, and William Blair in the past 90 days.

Analysts like Larimar Therapeutics more than other "medical" companies. The consensus rating for Larimar Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LRMR compares to other companies.


This page (NASDAQ:LRMR) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners